Sayana® Press

Alternative Name: Depo-subQ + Uniject

Description: Sayana Press contains 104 mg of depot medroxyprogesterone acetate (DMPA) per 0.65 mL dose and is administered via subcutaneous (SC) injection using the Uniject® injection system, a small pre-filled single use device.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Injectable

Duration Type: Short-acting

Duration: 3 months

  • one injection every 3 months

Dose: 104 mg

Active Pharmaceutical Ingredient (API):
  • medroxyprogesterone acetate

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Pfizer, PATH, USAID

Project Phase: Limited Market Availability

Development Stage: SRA/WHO PQ Approved

Active Development: Yes

Status Details:
  • Pfizer registered depo-subQ provera 104, the same drug in Sayana Press, with the US FDA in 2004. Sayana and Sayana Press are also registered with the UK Medicines and Healthcare Products Regulatory Agency (MHRA). It was approved in the European Union via procedure number UK/H/0960/002UK/H/0960/002.
  • Sayana Press is being introduced into Bangladesh, Burkina Faso, Niger, Senegal, and Uganda in 2014.

Additional Information


Vertical Tabs